这篇文章不错，转发给_老虎社区_美港股上老虎 - 老虎社区

这篇文章不错，转发给大家看看

@同壁财经：合成生物学技术应用受关注，港股创新药ETF（159567）上行，荣昌生物、石药集团、康哲药业、康希诺生物等领涨

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":341245043708128,"tweetId":"341245043708128","gmtCreate":1724332327944,"gmtModify":1724332975099,"author":{"id":3542598338700662,"idStr":"3542598338700662","authorId":3542598338700662,"authorIdStr":"3542598338700662","name":"丁征武_8782","avatar":"https://static.tigerbbs.com/ecad9f9ccaf13ae5f92695731cf4a1fd","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":1,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body>这篇文章不错，转发给大家看看</body></html>","htmlText":"<html><head></head><body>这篇文章不错，转发给大家看看</body></html>","text":"这篇文章不错，转发给大家看看","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/341245043708128","repostId":310714067230736,"repostType":1,"repost":{"magic":2,"id":310714067230736,"tweetId":"310714067230736","gmtCreate":1716885788130,"gmtModify":1716885791933,"author":{"id":4135467327484010,"idStr":"4135467327484010","authorId":4135467327484010,"authorIdStr":"4135467327484010","name":"同壁财经","avatar":"https://static.tigerbbs.com/4f343874740bbf9170eaa2762e82b228","vip":6,"userType":6,"introduction":"国内领先的新三板资讯平台","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":129,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"合成生物学技术应用受关注，港股创新药ETF（159567）上行，荣昌生物、石药集团、康哲药业、康希诺生物等领涨","html":"<html><head></head><body><p>5月28日，港股创新药概念逆势上升。盘面上，荣昌生物、石药集团、康哲药业、康希诺生物等领涨。港股创新药ETF（159567）表现活跃。 光大证券表示，近期合成生物学概念火爆，合成生物学采用了工程化的设计理念，改造或创造超越自然功能的人造生命体系或功能系统，广义而言可被界定为以生物基材料替代化石基材料、以生物技术路线替代传统化工技术路线的科技产业。其在生物医药领域的应用，主要在创新药及创新疗法、原料药和医药中间体两大方向。同时，若港股通红利税减免，则将对港股医药板块产生利好，部分高股息的医药股将受益于红利税减免政策。港股和创新药双重利好背景下，港股创新药ETF（159567）投资价值较高。</p>\n<ul>\n <li></li>\n</ul></body></html>","htmlText":"<html><head></head><body><p>5月28日，港股创新药概念逆势上升。盘面上，荣昌生物、石药集团、康哲药业、康希诺生物等领涨。港股创新药ETF（159567）表现活跃。 光大证券表示，近期合成生物学概念火爆，合成生物学采用了工程化的设计理念，改造或创造超越自然功能的人造生命体系或功能系统，广义而言可被界定为以生物基材料替代化石基材料、以生物技术路线替代传统化工技术路线的科技产业。其在生物医药领域的应用，主要在创新药及创新疗法、原料药和医药中间体两大方向。同时，若港股通红利税减免，则将对港股医药板块产生利好，部分高股息的医药股将受益于红利税减免政策。港股和创新药双重利好背景下，港股创新药ETF（159567）投资价值较高。</p>\n<ul>\n <li></li>\n</ul></body></html>","text":"5月28日，港股创新药概念逆势上升。盘面上，荣昌生物、石药集团、康哲药业、康希诺生物等领涨。港股创新药ETF（159567）表现活跃。 光大证券表示，近期合成生物学概念火爆，合成生物学采用了工程化的设计理念，改造或创造超越自然功能的人造生命体系或功能系统，广义而言可被界定为以生物基材料替代化石基材料、以生物技术路线替代传统化工技术路线的科技产业。其在生物医药领域的应用，主要在创新药及创新疗法、原料药和医药中间体两大方向。同时，若港股通红利税减免，则将对港股医药板块产生利好，部分高股息的医药股将受益于红利税减免政策。港股和创新药双重利好背景下，港股创新药ETF（159567）投资价值较高。","highlighted":1,"essential":1,"paper":2,"link":"https://laohu8.com/post/310714067230736","repostId":0,"isVote":1,"tweetType":1,"commentLimit":10,"symbols":["00867","01093","159567","09995","06185","513120","688331","688185"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":544,"xxTargetLangEnum":"ZH_CN"},"isVote":1,"tweetType":1,"viewCount":164,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":27,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/341245043708128"}